Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation

Amy P M Finch, Jan Lubinski, Pål Møller, Christian F. Singer, Beth Karlan, Leigha Senter, Barry Rosen, Lovise Maehle, Parviz Ghadirian, Cezary Cybulski, Tomasz Huzarski, Andrea Eisen, William D. Foulkes, Charmaine Kim-Sing, Peter Ainsworth, Nadine Tung, Henry T. Lynch, Susan Neuhausen, Kelly A. Metcalfe, Islay Thompson & 3 others Joan Murphy, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

255 Citations (Scopus)

Abstract

Purpose: The purposes of this study were to estimate the reduction in risk of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oophorectomy on all-cause mortality; and to estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort. Patients and Methods: Women with a BRCA1 or BRCA2 mutation were identified from an international registry; 5,783 women completed a baseline questionnaire and ≥ one follow-up questionnaires. Women were observed until either diagnosis of ovarian, fallopian tube, or peritoneal cancer, death, or date of most recent follow-up. Hazard ratios (HRs) for cancer incidence and all-cause mortality associated with oophorectomy were evaluated using time-dependent survival analyses. Results: After an average follow-up period of 5.6 years, 186 women developed either ovarian (n = 132), fallopian (n = 22), or peritoneal (n = 32) cancer, of whom 68 have died. HR for ovarian, fallopian, or peritoneal cancer associated with bilateral oophorectomy was 0.20 (95% CI, 0.13 to 0.30; P <.001). Among women who had no history of cancer at baseline, HR for all-cause mortality to age 70 years associated with an oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P <.001). Conclusion: Preventive oophorectomy was associated with an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 carriers and a 77% reduction in all-cause mortality.

Original languageEnglish
Pages (from-to)1547-1553
Number of pages7
JournalJournal of Clinical Oncology
Volume32
Issue number15
DOIs
StatePublished - May 20 2014

Fingerprint

Ovariectomy
Mutation
Mortality
Incidence
Fallopian Tubes
Neoplasms
Risk Reduction Behavior
Survival Analysis
Registries
Survival

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Finch, A. P. M., Lubinski, J., Møller, P., Singer, C. F., Karlan, B., Senter, L., ... Narod, S. A. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical Oncology, 32(15), 1547-1553. https://doi.org/10.1200/JCO.2013.53.2820

Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. / Finch, Amy P M; Lubinski, Jan; Møller, Pål; Singer, Christian F.; Karlan, Beth; Senter, Leigha; Rosen, Barry; Maehle, Lovise; Ghadirian, Parviz; Cybulski, Cezary; Huzarski, Tomasz; Eisen, Andrea; Foulkes, William D.; Kim-Sing, Charmaine; Ainsworth, Peter; Tung, Nadine; Lynch, Henry T.; Neuhausen, Susan; Metcalfe, Kelly A.; Thompson, Islay; Murphy, Joan; Sun, Ping; Narod, Steven A.

In: Journal of Clinical Oncology, Vol. 32, No. 15, 20.05.2014, p. 1547-1553.

Research output: Contribution to journalArticle

Finch, APM, Lubinski, J, Møller, P, Singer, CF, Karlan, B, Senter, L, Rosen, B, Maehle, L, Ghadirian, P, Cybulski, C, Huzarski, T, Eisen, A, Foulkes, WD, Kim-Sing, C, Ainsworth, P, Tung, N, Lynch, HT, Neuhausen, S, Metcalfe, KA, Thompson, I, Murphy, J, Sun, P & Narod, SA 2014, 'Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation', Journal of Clinical Oncology, vol. 32, no. 15, pp. 1547-1553. https://doi.org/10.1200/JCO.2013.53.2820
Finch, Amy P M ; Lubinski, Jan ; Møller, Pål ; Singer, Christian F. ; Karlan, Beth ; Senter, Leigha ; Rosen, Barry ; Maehle, Lovise ; Ghadirian, Parviz ; Cybulski, Cezary ; Huzarski, Tomasz ; Eisen, Andrea ; Foulkes, William D. ; Kim-Sing, Charmaine ; Ainsworth, Peter ; Tung, Nadine ; Lynch, Henry T. ; Neuhausen, Susan ; Metcalfe, Kelly A. ; Thompson, Islay ; Murphy, Joan ; Sun, Ping ; Narod, Steven A. / Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 15. pp. 1547-1553.
@article{7cd255d3e46c45b1977af9962e79332d,
title = "Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation",
abstract = "Purpose: The purposes of this study were to estimate the reduction in risk of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oophorectomy on all-cause mortality; and to estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort. Patients and Methods: Women with a BRCA1 or BRCA2 mutation were identified from an international registry; 5,783 women completed a baseline questionnaire and ≥ one follow-up questionnaires. Women were observed until either diagnosis of ovarian, fallopian tube, or peritoneal cancer, death, or date of most recent follow-up. Hazard ratios (HRs) for cancer incidence and all-cause mortality associated with oophorectomy were evaluated using time-dependent survival analyses. Results: After an average follow-up period of 5.6 years, 186 women developed either ovarian (n = 132), fallopian (n = 22), or peritoneal (n = 32) cancer, of whom 68 have died. HR for ovarian, fallopian, or peritoneal cancer associated with bilateral oophorectomy was 0.20 (95{\%} CI, 0.13 to 0.30; P <.001). Among women who had no history of cancer at baseline, HR for all-cause mortality to age 70 years associated with an oophorectomy was 0.23 (95{\%} CI, 0.13 to 0.39; P <.001). Conclusion: Preventive oophorectomy was associated with an 80{\%} reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 carriers and a 77{\%} reduction in all-cause mortality.",
author = "Finch, {Amy P M} and Jan Lubinski and P{\aa}l M{\o}ller and Singer, {Christian F.} and Beth Karlan and Leigha Senter and Barry Rosen and Lovise Maehle and Parviz Ghadirian and Cezary Cybulski and Tomasz Huzarski and Andrea Eisen and Foulkes, {William D.} and Charmaine Kim-Sing and Peter Ainsworth and Nadine Tung and Lynch, {Henry T.} and Susan Neuhausen and Metcalfe, {Kelly A.} and Islay Thompson and Joan Murphy and Ping Sun and Narod, {Steven A.}",
year = "2014",
month = "5",
day = "20",
doi = "10.1200/JCO.2013.53.2820",
language = "English",
volume = "32",
pages = "1547--1553",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "15",

}

TY - JOUR

T1 - Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation

AU - Finch, Amy P M

AU - Lubinski, Jan

AU - Møller, Pål

AU - Singer, Christian F.

AU - Karlan, Beth

AU - Senter, Leigha

AU - Rosen, Barry

AU - Maehle, Lovise

AU - Ghadirian, Parviz

AU - Cybulski, Cezary

AU - Huzarski, Tomasz

AU - Eisen, Andrea

AU - Foulkes, William D.

AU - Kim-Sing, Charmaine

AU - Ainsworth, Peter

AU - Tung, Nadine

AU - Lynch, Henry T.

AU - Neuhausen, Susan

AU - Metcalfe, Kelly A.

AU - Thompson, Islay

AU - Murphy, Joan

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2014/5/20

Y1 - 2014/5/20

N2 - Purpose: The purposes of this study were to estimate the reduction in risk of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oophorectomy on all-cause mortality; and to estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort. Patients and Methods: Women with a BRCA1 or BRCA2 mutation were identified from an international registry; 5,783 women completed a baseline questionnaire and ≥ one follow-up questionnaires. Women were observed until either diagnosis of ovarian, fallopian tube, or peritoneal cancer, death, or date of most recent follow-up. Hazard ratios (HRs) for cancer incidence and all-cause mortality associated with oophorectomy were evaluated using time-dependent survival analyses. Results: After an average follow-up period of 5.6 years, 186 women developed either ovarian (n = 132), fallopian (n = 22), or peritoneal (n = 32) cancer, of whom 68 have died. HR for ovarian, fallopian, or peritoneal cancer associated with bilateral oophorectomy was 0.20 (95% CI, 0.13 to 0.30; P <.001). Among women who had no history of cancer at baseline, HR for all-cause mortality to age 70 years associated with an oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P <.001). Conclusion: Preventive oophorectomy was associated with an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 carriers and a 77% reduction in all-cause mortality.

AB - Purpose: The purposes of this study were to estimate the reduction in risk of ovarian, fallopian tube, or peritoneal cancer in women with a BRCA1 or BRCA2 mutation after oophorectomy, by age of oophorectomy; to estimate the impact of prophylactic oophorectomy on all-cause mortality; and to estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort. Patients and Methods: Women with a BRCA1 or BRCA2 mutation were identified from an international registry; 5,783 women completed a baseline questionnaire and ≥ one follow-up questionnaires. Women were observed until either diagnosis of ovarian, fallopian tube, or peritoneal cancer, death, or date of most recent follow-up. Hazard ratios (HRs) for cancer incidence and all-cause mortality associated with oophorectomy were evaluated using time-dependent survival analyses. Results: After an average follow-up period of 5.6 years, 186 women developed either ovarian (n = 132), fallopian (n = 22), or peritoneal (n = 32) cancer, of whom 68 have died. HR for ovarian, fallopian, or peritoneal cancer associated with bilateral oophorectomy was 0.20 (95% CI, 0.13 to 0.30; P <.001). Among women who had no history of cancer at baseline, HR for all-cause mortality to age 70 years associated with an oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P <.001). Conclusion: Preventive oophorectomy was associated with an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer in BRCA1 or BRCA2 carriers and a 77% reduction in all-cause mortality.

UR - http://www.scopus.com/inward/record.url?scp=84903818387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903818387&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.53.2820

DO - 10.1200/JCO.2013.53.2820

M3 - Article

VL - 32

SP - 1547

EP - 1553

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

ER -